Zobrazeno 1 - 10
of 13
pro vyhledávání: '"van Berge Henegouwen JM"'
Autor:
Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wijngaart H; Department of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Chalabi M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Devriese LA; Division Beeld & Oncologie, Department of Medical Oncology, Utrecht University Medical Center, Utrecht, the Netherlands., Erdkamp FLG; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geleen, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Center, location VUMC, Cancer Center Amsterdam, Amsterdam, the Netherlands., de Jonge MJA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Kerver ED; Department of Medical Oncology, OLVG, Amsterdam, the Netherlands., Bins AD; Department of Medical Oncology, Amsterdam University Medical Center, location VUMC, Cancer Center Amsterdam, Amsterdam, the Netherlands., Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Notohardjo JCL; Department of Medical Oncology, Amsterdam University Medical Center, location VUMC, Cancer Center Amsterdam, Amsterdam, the Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam University Medical Center, location VUMC, Cancer Center Amsterdam, Amsterdam, the Netherlands., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., van de Haar J; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 01; Vol. 30 (19), pp. 4339-4351.
Autor:
Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Leek LVM; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands., Hoes LR; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wijngaart H; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.; Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., van de Haar J; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Ommen-Nijhof A; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands., de Jonge MJA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Hoeben A; Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.; Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Wessels LFA; Oncode Institute, Utrecht, the Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3735-3746.
Autor:
van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Hoes LR; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., van der Wijngaart H; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., de Vos FYF; Department of Medical Oncology, Utrecht University Medical Center, Utrecht, the Netherlands., Grünberg K; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3937-3943.
Autor:
Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Leiden, The Netherlands., van der Wijngaart H; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Spiekman IA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van Beek DM; Hartwig Medical Foundation, Amsterdam, The Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Jansen AM; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WW; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., van Herpen CM; Department of Medical Oncology, Radboud Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
Publikováno v:
The Journal of pathology [J Pathol] 2024 Jul; Vol. 263 (3), pp. 288-299. Date of Electronic Publication: 2024 May 15.
Autor:
Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Looze EJ; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van Berge Henegouwen JM; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Simes RJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sjoquist KM; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., van der Wijngaart H; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Sebastian L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Espinoza D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands., Lin FP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.
Publikováno v:
International journal of cancer [Int J Cancer] 2023 Oct 01; Vol. 153 (7), pp. 1413-1422. Date of Electronic Publication: 2023 Jul 10.
Autor:
Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van Berge Henegouwen JM; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Wijngaart H; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Cancer Centre Utrecht, Utrecht, the Netherlands., Opdam FL; Department of Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., de Jonge MJA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Cirkel GA; Department of Medical Oncology, Meander, Amersfoort, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Centre, location VUMC, Amsterdam, the Netherlands., Hoeben A; Department of Medical Oncology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands., Kerver ED; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands., Bins AD; Department of Medical Oncology, Amsterdam University Medical Centre, location AUMC, Amsterdam, the Netherlands., Erdkamp FGL; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geelen, the Netherlands., van Rooijen JM; Department of Medical Oncology, Martini Hospital, Groningen, the Netherlands., Houtsma D; Department of Medical Oncology, Haga Hospital, The Hague, the Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, the Netherlands., de Groot JB; Department of Medical Oncology, Isala, Zwolle, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.; Oncode Institute, Utrecht, the Netherlands. e.voest@nki.nl.
Publikováno v:
BMC cancer [BMC Cancer] 2023 Mar 04; Vol. 23 (1), pp. 205. Date of Electronic Publication: 2023 Mar 04.
Autor:
van Berge Henegouwen JM; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Oncode Institute, the Netherlands., Jebbink M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Hoes LR; Oncode Institute, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Wijngaart H; Oncode Institute, the Netherlands; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Zeverijn LJ; Oncode Institute, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Velden DL; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., van Werkhoven E; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Wekken AJ; Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Voest EE; Oncode Institute, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Smit EF; Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: a.j.gelderblom@lumc.nl.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Aug; Vol. 171, pp. 114-123. Date of Electronic Publication: 2022 Jun 15.
Autor:
van Berge Henegouwen JM; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van der Wijngaart H; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Zeverijn LJ; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoes LR; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meertens M; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. A.J.Gelderblom@lumc.nl.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jul; Vol. 90 (1), pp. 97-104. Date of Electronic Publication: 2022 May 22.
Autor:
Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands., van Berge Henegouwen JM; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., van der Wijngaart H; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Velden DL; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands., van de Haar J; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., de Leng WJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., van Werkhoven E; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands., Huitema ADR; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands., Gort EH; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., de Groot JWB; Isala Oncology Center, Isala, Zwolle, the Netherlands., Kerver ED; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands., de Groot DJ; Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands., Erdkamp F; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geleen, the Netherlands., Beerepoot LV; Department of Medical Oncology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, the Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van der Graaf WTA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Labots M; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, the Netherlands., Morreau H; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Lolkema MP; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, the Netherlands., Cuppen E; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Hartwig Medical Foundation, Amsterdam, the Netherlands.; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 01; Vol. 28 (7), pp. 1402-1411.
Autor:
van der Wijngaart H; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Hoes LR; Oncode Institute, Utrecht, the Netherlands.; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Berge Henegouwen JM; Oncode Institute, Utrecht, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Rapenburg, Leiden, the Netherlands., van der Velden DL; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Zeverijn LJ; Oncode Institute, Utrecht, the Netherlands.; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands., van Werkhoven E; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Hoeben A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Rapenburg, Leiden, the Netherlands., Voest EE; Oncode Institute, Utrecht, the Netherlands.; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. henk.verheul@radboudumc.nl.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Nov 15; Vol. 27 (22), pp. 6106-6114. Date of Electronic Publication: 2021 Sep 02.